How do I hire a fractional CRO for a biotech business?

What does a fractional CRO actually do for a biotech company?

A fractional CRO is a part-time, senior revenue owner who takes accountability for the entire commercial engine — not just sales, but pricing, forecasting, channel and partnership strategy, marketing-to-revenue alignment, and the operating cadence that connects them. Unlike a consultant who diagnoses and hands you a report, a fractional CRO carries a number and sits inside your leadership meetings. Unlike a full-time CRO, they split their week across your business and typically one or two others, giving you executive experience at a fraction of the cost and commitment.

In biotech specifically, the job splits along your business model. For a therapeutics company, a fractional CRO is often really a chief business officer in disguise — the revenue events are out-licensing deals, milestone payments, and partnership term sheets, so the skill is deal architecture and pharma-partner relationships, not a quota-carrying sales floor. For a diagnostics or life-sciences tools company, revenue looks more conventional: a repeatable sales motion into hospitals, reference labs, CROs, or academic core facilities, where the CRO builds pipeline, hires reps, and installs a forecast. For a CDMO or services business, it is enterprise relationship selling with long procurement cycles. Naming which of these you are is the single most important step, because it determines the entire candidate profile you should be recruiting against. You can see how this maps to broader commercial-leadership scoping in the PULSE knowledge base.

The practical deliverables in the first 90 days are usually the same across models: a revenue model the board trusts, a segmented view of where money actually comes from, a fixed pricing and packaging framework, a hiring plan for the commercial team, and an operating rhythm (pipeline reviews, forecast calls, win-loss analysis) that outlives the fractional's tenure. A good one is building a machine you can eventually run without them.

When should a biotech business hire a fractional CRO instead of a full-time one?

The fractional model fits three specific situations. First, you are pre-scale: revenue exists or is imminent, but not at a level that justifies a 350,000-to-600,000-US-dollar all-in executive package plus meaningful equity. Second, the problem is bounded: you need to stand up a commercial function, fix a broken pricing model, or land the first repeatable sales motion — a project with a finish line, not a permanent seat. Third, you are between a founder-led sale and a real revenue org: the scientific founder has closed the first handful of deals on credibility and relationships, but that does not scale, and you are not yet ready to bet the runway on a permanent hire you might mis-pick.

Hire full-time instead when revenue is already the center of gravity of the company — when you need someone in every customer escalation, when the team is large enough that part-time attention starves it, or when investors are underwriting the next round specifically on commercial leadership being locked in. A fractional CRO who is doing the job well will often tell you when you have outgrown them; that honesty is a feature of the model, and a red flag if it is absent.

The decision is rarely permanent. Many biotechs use a fractional CRO precisely as a bridge — the person stands up the function, proves the motion, and either converts to full-time equity or hands off to a permanent hire they helped recruit. Treating the engagement as a one-way door is a mistake; the value is that it is reversible and re-scopeable as the company changes underneath it.

What biotech-specific experience should the fractional CRO have?

This is where most hires go wrong. A fractional CRO with a brilliant SaaS or generic B2B track record will drown in biotech's structural realities, and the failure will be expensive and slow to surface. Insist on domain-specific pattern recognition in four areas.

Reimbursement, regulatory, and pricing literacy. For diagnostics especially, revenue is gated by reimbursement — CPT codes, payer coverage decisions, and the difference between a test that is clinically validated and one that actually gets paid for. A CRO who cannot speak to reimbursement pathways will price into a wall. For therapeutics and regulated products, the interplay of FDA milestones with commercial timing shapes the entire revenue model. This literacy is not optional; it is the difference between a plausible forecast and fiction. The reimbursement-and-pricing primer on PULSE is a useful shared reference to hand a candidate and gauge their fluency.

Channel and partner architecture. Biotech revenue often flows through distributors, reference labs, group purchasing organizations, or pharma partners rather than direct. The CRO should have built or managed at least one of these indirect motions, because the economics, contracts, and incentive design differ sharply from direct enterprise sales.

Scientific credibility with buyers. In life sciences, the buyer is frequently a PhD, and a sales leader who cannot hold a technically credible conversation loses the room. You are not hiring a scientist, but you are hiring someone who has earned trust with scientific buyers before and can coach reps to do the same.

The filtering diagram above matters because a candidate who is exceptional for a diagnostics company may be actively wrong for a therapeutics business-development need. Match the axis, then test for the gate underneath it.

How do I structure the engagement, scope, and KPIs?

Write a one-page scope before you talk money. It should name the business model, the single most important revenue outcome for the next two quarters, the weekly time commitment, the decision authority the CRO holds, and the specific KPIs you will review. Vagueness here is the most common cause of a fractional engagement quietly failing — the CRO fills undefined time with low-value activity, and six months later you have spent 90,000 US dollars on nice conversations and no revenue system.

Anchor KPIs to your model. Do not import SaaS metrics wholesale into a business with 18-month sales cycles, because you will have no signal for a year. Instead, pick leading indicators appropriate to biotech: qualified pipeline created and staged, number of active buying committees engaged, partner or distributor agreements signed, pricing framework shipped and adopted, forecast accuracy against a rolling model, and reps hired and ramped. The table below shows how KPIs shift by model.

Set the cadence explicitly: a weekly pipeline and forecast review, a monthly board-ready revenue update, and a 90-day checkpoint where you jointly decide whether to extend, re-scope, or convert. Give the CRO real authority over pricing and commercial hiring within agreed guardrails — a fractional leader stripped of decision rights becomes an expensive advisor, and the whole point of the model is that they own outcomes, not just opinions. For a deeper operating-rhythm template, see the revenue cadence guide in the PULSE library.

Contract terms should protect both sides. Use a defined initial term (often three to six months) with a clean renewal decision, a notice period of 30 days, clear IP and confidentiality provisions appropriate to a company holding sensitive scientific and clinical data, and a conflict-of-interest clause given that fractional executives serve multiple clients — you do not want your CRO simultaneously advising a direct competitor.

What does a fractional biotech CRO cost, and how do I structure pay?

Compensation for fractional CROs generally runs on a monthly retainer tied to time commitment. Across the market, a fractional CRO engagement commonly lands somewhere between roughly 200 and 400 US dollars per hour, or a monthly retainer in the ballpark of 8,000 to 25,000 US dollars depending on hours, seniority, and scope. A one-day-per-week engagement sits at the lower end; a two-to-three-day commitment with team-build responsibility sits higher. These are directional ranges, not quotes — actual numbers vary by market, the individual's track record, and how hot demand is for their specific domain, so validate against real conversations rather than treating any figure as fixed.

Biotech tends to price at the upper end of the fractional band for two reasons: the domain expertise is scarce, and the sales cycles mean the CRO carries risk over a longer horizon before results show. Do not anchor on the cheapest bid. A generalist at 8,000 US dollars a month who mis-forecasts a biotech pipeline for two quarters is far more expensive than a domain expert at 18,000 US dollars a month who prices correctly the first time.

Structure the deal in three components where possible. First, a base retainer for the guaranteed time and availability. Second, a modest performance component tied to the leading KPIs you defined — a bonus on partner agreements signed, pipeline milestones, or a pricing framework adopted; keep this aligned to inputs the CRO controls, not to revenue that may not land for a year. Third, for engagements you expect to convert or that demand real skin in the game, a small equity or advisory-share grant, vesting over the engagement, which aligns the fractional leader to long-term value in a way biotech's long cycles otherwise discourage. Be cautious with equity-heavy structures for a part-time role — reserve meaningful equity for a genuine path to a permanent seat. The compensation-design reference on PULSE breaks down retainer-versus-equity trade-offs in more detail.

Avoid pure commission structures for a fractional biotech CRO. Commission-only pay assumes a fast, attributable sales cycle that biotech does not have; it pushes the CRO toward short-term deals over the durable revenue architecture you actually hired them to build, and it will not attract the caliber of leader you want.

How do I find, vet, and onboard the right candidate?

Source through channels where senior life-sciences commercial leaders actually congregate: fractional-executive platforms and networks, life-sciences-specific search firms, your investors' operating partners and portfolio networks, and warm referrals from other biotech founders who have used the model. Investor introductions are especially valuable because a VC who has watched a fractional CRO perform across portfolio companies gives you a reference no interview can match. Cold marketplaces can work, but weight referrals heavily given how domain-specific the fit must be.

Vet in three layers. Domain proof: make them walk through two real biotech revenue outcomes they personally owned, with specifics — the buying committee, the cycle length, the pricing decision, what went wrong. Generic answers here are disqualifying. Reference depth: call founders they served, not just the logos — ask what the CRO actually changed, whether the forecast held, and whether they would rehire. Fit and honesty: a strong fractional CRO will push back on your assumptions in the interview and tell you where your revenue plan is unrealistic; a candidate who only agrees with you is selling, not leading.

Onboard fast and concretely. In week one, give full access to your CRM, pipeline data, pricing history, and any commercial contracts, and put them in front of two or three real customers or partners. The fractional model only works if the CRO reaches operating depth quickly, and that requires you to remove information friction on day one. Set the 90-day checkpoint at the start so both sides know the engagement is being measured. Establish clearly who on your team the CRO directs — even part-time, they need real reporting lines to move the commercial function, or they become a well-paid observer.

Related questions

How is a fractional CRO different from a fractional CBO in biotech?

A fractional CRO owns the repeatable commercial engine — sales, pricing, channels. A fractional CBO owns deal-making — licensing, partnerships, milestone negotiations. Pre-revenue therapeutics usually need a CBO; diagnostics and tools companies need a CRO.

Can a pre-revenue biotech benefit from a fractional CRO?

Sometimes, but often what you actually need is a fractional CBO or business-development leader for partnering deals. If your near-term revenue is licensing rather than product sales, hire for deal architecture, not a sales floor.

How long should a fractional CRO engagement last in biotech?

Typically 6 to 18 months. Long enough to stand up the commercial function and prove a motion given biotech's slow cycles, but with quarterly re-scope decisions and a defined path to conversion, hand-off, or exit.

Should the fractional CRO have equity in my biotech?

Small vesting equity or advisory shares can align a long engagement, especially one on a conversion path. Avoid heavy equity for genuinely part-time work; reserve it for a real route to a permanent seat.

What is the biggest risk of hiring a fractional CRO in biotech?

Hiring a domain generalist who mis-reads biotech's long sales cycles and reimbursement gates, forecasts like a SaaS seller, and churns the team chasing pipeline that was never going to close on their timeline.

FAQ

How many hours per week does a fractional biotech CRO typically work?

Do fractional CROs work with multiple biotech companies at once? Yes, that is core to the model — they typically serve one to three clients simultaneously. Insist on a conflict-of-interest clause so yours is never advising a direct competitor, and confirm their bandwidth matches your scope.

What KPIs should I hold a fractional biotech CRO to in the first 90 days? Leading indicators, not lagging revenue: qualified pipeline created, active buying committees engaged, a shipped pricing framework, partner or distributor agreements advanced, forecast accuracy against a model, and reps hired and ramped.

Is a fractional CRO worth it for a diagnostics startup pre-reimbursement? Often yes, because pricing and payer strategy must be built before reimbursement lands, not after. A CRO fluent in coverage pathways can prevent you from pricing into a wall and building a motion that never gets paid.

How do I know when to convert a fractional CRO to full-time? When revenue becomes the company's center of gravity, the team outgrows part-time attention, or investors underwrite the next round on locked-in commercial leadership. A good fractional CRO will flag the transition before you have to ask.

Can a fractional CRO help with fundraising in biotech? Yes — a credible revenue model, defensible pricing, and a real pipeline are exactly what commercial-stage investors diligence. A strong fractional CRO makes your revenue story investor-ready and often joins diligence calls to defend the model.

What should be in a fractional CRO contract for a biotech? A defined term with renewal decision, notice period, scope and KPIs, decision authority, retainer and any performance or equity terms, plus strong IP, confidentiality, and conflict-of-interest clauses given the sensitivity of scientific and clinical data.

Should the fractional CRO manage my existing sales reps directly? Yes, within agreed guardrails they need real reporting lines to move the function. A fractional leader stripped of authority over the commercial team becomes an expensive advisor rather than an accountable revenue owner.

Sources

• Harvard Business Review — The Fractional Executive Trend
• MassBio — Massachusetts Biotechnology Council Industry Resources
• BIO — Biotechnology Innovation Organization
• Nature Biotechnology — Commercialization and Business Coverage
• Centers for Medicare and Medicaid Services — Coverage and Reimbursement
• U.S. Food and Drug Administration — Medical Devices and Diagnostics
• STAT News — Biotech Business and Commercial Strategy
• SHRM — Society for Human Resource Management Executive Compensation

Related on PULSE

• [How do I hire a fractional CRO for a biotech business in 2027?](/knowledge/tl9249)
• [How do I hire a fractional CRO for a martech business in 2027?](/knowledge/tl9039)
• [How do I hire a fractional CRO for a proptech business in 2027?](/knowledge/tl9059)
• [How do I hire a fractional CRO for a healthtech business in 2027?](/knowledge/tl9019)
• [How do I hire a fractional CRO for a logistics business in 2027?](/knowledge/tl9043)
• [How do I hire a fractional CRO for a insurtech business in 2027?](/knowledge/tl9055)